Trial Profile
A Phase 2 Randomized Sequence Open Label Expanded Safety and Acceptability Study of Oral Emtricitabine/Tenofovir Disoproxil Fumarate Tablet and Rectally-Applied Tenofovir Reduced-Glycerin 1% Gel
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 27 Apr 2022
Price :
$35
*
At a glance
- Drugs Tenofovir (Primary) ; Emtricitabine/tenofovir disoproxil fumarate
- Indications HIV infections
- Focus Adverse reactions; Therapeutic Use
- Acronyms MTN017
- Sponsors CONRAD
- 01 Apr 2022 Results of pharmacokinetic and pharmacodynamic assessment published in the AIDS Research and Human Retroviruses
- 31 May 2019 According to an Orion Biotechnology Canada Media release, results are presented at the International Journal of STD & AIDS.
- 25 Feb 2016 Results presented at the 23rd Conference on Retroviruses and Opportunistic Infections